As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >


Pépinière Genopole Entreprises
4, rue Pierre Fontaine – Genopole Campus 3
91058 EVRY Cedex – FRANCE
Phone : +33 1 81 70 76 82
Email :

PRESTAT Antoine : President
Web Site >
PEP-Therapy - Genopole's Company - logo 2021 PEP-Therapy - Genopole's Company - logo 2021

#Health / Well-being #Therapeutics

  • Cell Penetrating & Interfering Peptides
  • Targeted therapies
  • Cancer
  • Companion biomarkers

Field of Activity

PEP-Therapy develops innovative peptides as targeted therapies in oncology.
The company operates a unique therapeutic technology based on cell penetrating & interfering peptides (CP&IP).
These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.


PEP-Therapy is building upon research performed at the Sorbonne University (formerly UPMC, France’s leading scientific and medical university) and Institut Curie (Europe’s leading cancer center).

These institutions contribute their scientific and medical expertise, unique preclinical models and clinical trial capacities to the PEP-Therapy project.

Description of the Products / Services / Technology

PEP-010 is PEP-Therapy’s first CP&IP-based product and a first-in-class targeted approach to cancer treatment. PEP-010 specifically disrupts the Caspase9/PP2A protein-protein interaction.

In so doing, it:

  • triggers apoptosis (death) in cancer cells without harming healthy cells;
  • leaves the other signaling pathways intact, limiting therefore the risk of side effects.

PEP-Therapy has also pre-validated predictive companion biomarkers for the identification of patients likely to respond well to PEP-010 treatment.

Following upon the proof of concept for its first product, PEP-Therapy will accelerate the use of its CP&IP technology, both internally and in partnerships with pharmaceutical & biotech companies (licensing, co-developments, etc.), on other intracellular targets.

The company is currently developing a second drug candidate, PEP-020, for the treatment of uveal melanoma, a rare disease with high medical need.

Customer references / Collaborations / Highlights

The drug-candidate PEP-010 has demonstrated preclinical proof of concept (Arrouss et al., 2013) in:

  • the cells of patients with chronic lymphocytic leukemia, where PEP-010 induces death of tumor B cells without affecting healthy cells (T, NK, monocytes), demonstrating the specificity of tumor targeting;
  • patient-derived xenograft (PDX) animal models, where PEP-010 inhibits tumor growth of breast (including triple-negative) and ovary primary tumors.

Additionally, GLP-toxicity studies in murine and simian models have been completed, showing good systemic tolerance for PEP-010.
The Phase I/II clinical trial is being prepared in partnership with Institut Curie and the Gustave Roussy Cancer Centre.

PEP-Therapy raised €2.5 million in initial funding, invested by the Quadrivium 1 seed fund, managed by Seventure Partners, and Dr. Bernard Majoie, former Chairman and CEO of Laboratoires Fournier.

Collaborations sought

Investors and pharma/biotech companies for the development of PEP-Therapy’s initial therapeutic products and biomarkers, and for the exploitation of the CP&IP technology.

  • Further Information


    Portfolio of three  patent families covering the CP&IP technology, the company’s first therapeutic products.


    In vivo proof of concept using predictive PDX animal models (Institut Curie); biomarkers for treatment response prediction; GLP-Tox successfully completed; clinical trial in preparation with Institut Curie and the Gustave Roussy Cancer Centre.

    Innovation assets:

    Cell penetrating & interfering peptides (CP&IP) technology.

    First-in-class therapeutic peptide in oncology.

Genopole’s Companies


In same field

DeepTope - Genopole's company


– Characterization of antigen / antibody interactions (epitope / paratope) – Optimization of therapeutic antibodies

Theranovir - Genopole's Company


Biotechnology, R&D, Drug development, oncology, obesity, infectious diseases

Synsight - Genopole's Company


Synsight is a company specializing in the discovery and preclinical development of new therapeutic molecules, based on a proprietary, integrated platform, combining artificial intelligence, molecular modeling and a functional experimental screening approach of High-Content Screening (HCS ).

Santen - Genopole's Company


Santen SAS has developed its own sales force to commercialize ophthalmic products in France while Novagali Innovation Center is a center of excellence for Santen Group dedicated to research and development of innovative ophthalmic treatments for all segments of the eye.

Pharnext - Genopole's company

Pharnext SA

Pharnext develops new therapies and biomarkers based on network pharmacology with a proprietary discovery platform. The company is focused on pathologies with high unmet medical needs. These include neurodegenerative, orphan and common diseases (Charcot-Marie-Tooth disease Type 1A, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS)).

Pharming - Genopole's company - Logo 2021


Pharming specializes in the production of recombinant proteins in transgenic rabbit milk.

Genosafe - Genopole's Company


GenoSafe is a full contract research and consulting organization specialized in evaluating the quality, safety and efficacy of innovative biological products. Our goal is to enable our clients to move their products along clinical development rapidly and efficiently.

Généthon - Genopole's Laboratory


Discovery, development and production of innovative therapies for rare genetic diseases, notably neuromuscular diseases.

Eukarÿs - Genopole's company


By means of its autonomous messenger RNA synthesis platform, Eukarÿs develops 1) systems for the bioproduction of viruses and recombinant proteins and 2) preventative vaccines for viral infectious diseases and treatments in immuno-oncology.



Enterome develops and commercializes therapies for disorders associated with disruption of the intestinal microbiota.

Logo Ab Science - Genopole's company

AB Science

Research, development and commercialization of tyrosine kinase inhibitors as targeted therapy for pathologies with unmet medical needs.

View all >
With the support from
Région île de France